Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAC scoring pinpoints stenoses in asymptomatic diabetes patients

Key clinical point: Modeling suggests that incorporating coronary artery calcium (CAC) scoring into a silent myocardial ischemia screening algorithm may help avoid missed coronary stenoses suitable for revascularization among diabetes patients with no cardiovascular symptoms despite certain risk factors.

Major finding: Screening only patients with peripheral artery disease or severe nephropathy would have missed 6 patients with coronary stenosis suitable for revascularization among the 275 patients who did not meet those target organ damage criteria, while zero patients would be missed by screening patients who met those criteria or had a high CAC score.

Study details: A study of 416 diabetes patients with diabetes at very high cardiovascular risk but with no cardiac history or symptoms.

Disclosures: The presenting author provided disclosures related to Merck Sharp Dohme, Novo Nordisk, Pierre Fabre, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Daiichi-Sankyo, and others.

Citation:

Berkane N et al. ADA 2020, Abstract 8-OR.